Biogen strikes $85M Alcyone buyout, securing tech for spinal drug delivery

18 Sep 2025
·
Deals
www.fiercebiotech.com
License out/inOligonucleotideAcquisitionGene TherapyClinical Study
Biogen has agreed to divest Alcyone Therapeutics' remaining therapeutic assets to a new independent company.
Biogen has given Alcyone TheAlcyone Therapeutics role in its drug delivery strategy, paying $85 million to buy the biotech and take control of an implant for getting medicines into the spinal canal.
Biogenal is centeAlcyone Therapeutics, a system designed to provide access to cerebrospinal fluid (CSF). Currently, people who receive drugs that are delivered to the CSF, such as Biogen’s Spinraza, undergo lumbar punctures each time at a hospital or outpatient site with expertise in intrathecal administration. An implant such as ThecaFlex DRx could eliminate the risks associated with repeated lumbar punctures.
Back in 2023, Biogen paid Alcyone $10 million for an exclusive license to use the technology in treatments for spinal muscular atrophy and amyotrophic lateral sclerosis (ALS). ThatBiogenincSpinraza to $41 million in milestones and gave Biogen the option to expand the collaboration to cover other antisense oligonucleotides from its portfolio or pipeline.
With clinical Biogen of ThAlcyone DRx and nusinersen, the active ingredient in Spinraza, underway, Biogen has sspinal muscular atrophyng thamyotrophic lateral sclerosis (ALS)yone employees will join Biogen and, with the Big Biotech’s reBiogens behind them, drive development, manufacturing and commercialization of the delivery technology.
Biogen is aiming to introduce the drug delnusinersenem for Spinraza in early 20Spinrazaided its cliBiogentrials are successful and regulators sign off on the technology. DAlcyonem the Spinraza studieBiogen inform Biogen’Big Biotechexpand the use of the system to its broader portfolio of therapies.
Biogenmpany’s portfolio won’t be swelled by drugs in develoSpinraza Alcyone. Focused on ThecaFlex DRx, Biogen has agreed to divest Alcyone’s remaining therapeutic assets to a new indepSpinrazaompany, Neela TherapeBiogen
Alcyone, which raised money in April to advance its pipeline, is runAlcyoneclinical trial of a gene theBiogenor CLN3 Batten diseaseAlcyoneeclinical tests of a small molecule in ALS.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!